SAN JUAN CAPISTRANO, Calif.–(Business enterprise WIRE)–Allegro Ophthalmics, LLC, a privately held biopharmaceutical enterprise targeted on the enhancement of novel integrin-regulating therapies for the cure of ocular diseases, these days introduced that William J. Hyperlink, PhD, has been appointed chairman by the company’s board of directors and that Stephanie Yee was named vice president of finance.
Vicken Karageozian, M.D., president and CEO of Allegro Ophthalmics, reported, “I am thrilled that Monthly bill has agreed to provide as our board chairman and delighted to endorse Stephanie as VP of finance and member of the executive group. Monthly bill is a pioneer whose huge expertise in developing and main prosperous ophthalmic companies is a great asset at this exciting minute at Allegro. Stephanie has a deep and in depth document in running the fiscal operations of a variety of corporations. Their appointments will help to guarantee Allegro’s results as we progress our drug candidates—risuteganib for the cure of intermediate non-exudative age-related macular degeneration (dry AMD) and ALG-1007 for the therapy of dry eye disease—through scientific growth.”
Dr. Link is founder and principal of Traveling L. Partners and is a founder and managing director of Versant Ventures. Prior to Versant, Dr. Url was a common spouse at Brentwood Venture Capital. With extra than two decades of operations encounter in the healthcare sector, Dr. Website link has a verified report of setting up and managing substantial, successful health-related products corporations, together with Chiron Eyesight wherever he was co-founder, chairman and CEO until it was sold to Bausch + Lomb in 1997. Dr. Url also founded and served as president of American Clinical Optics (AMO), a division of American Hospital Provide Company, which was offered to Allergan in 1986.
Bringing more than two many years of accounting and finance knowledge to Allegro, Ms. Yee has held a number of administration roles at ZO Pores and skin Well being and ClariPhy Communications, as effectively as at Emulex Corporation, which was acquired by Avago Systems and later on merged with Broadcom. All through her tenure, she became the resident SEC reporting expert and managed thanks diligence and integration for three acquisitions. Ms. Yee also worked at IntraLase. When IntraLase was obtained by AMO, Ms. Yee coordinated the company’s integration into AMO, now portion of Johnson & Johnson.
About Allegro Ophthalmics, LLC
Allegro Ophthalmics, LLC is a privately held biopharmaceutical organization centered on the development of novel integrin-regulating therapies for the therapy of ocular health conditions. Pre-clinical knowledge recommend that risuteganib (Luminate®), Allegro’s lead investigational compound in retina, could concurrently act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in health conditions, these types of as dry AMD. A U.S. Stage 2a research with risuteganib in considerably less advanced dry AMD met its key endpoint of vision restoration. Growing its integrin-regulating portfolio, Allegro has designed ALG-1007 for topical use in dry eye condition. ALG-1007 shown promising outcomes in an ex-U.S. proof-of-principle study in individuals and is presently becoming evaluated in a 2nd and more substantial ex-U.S. Stage 2 examine. For much more information, go to www.allegroeye.com.
Risuteganib (Luminate®) and ALG-1007 are investigational prescription drugs and are not approved for industrial sale.
Luminate® is a registered trademark of Allegro Ophthalmics, LLC.